Table 3.

Prognostic value of the parameters included in the histological staging system.

		Disease-free interval		Overall survival		Cancer-specific survival
		HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
UNIVARIATE ANALYSES
Invasiveness	Invasive vs. in situ	5.07 (3.55–7.24)	<0.0001	2.86 (2.28–3.58)	<0.0001	6.78 (4.97–9.26)	<0.0001
Pathologic tumor size	>20 vs. ≤ 20 mm	1.48 (1.06–2.06)	<0.0001	1.82 (1.47–2.26)	<0.0001	1.81 (1.35–2.42)	<0.0001
Lymphovascular invasion	LVI+ vs. LVI–	3.87 (2.66–5.63)	<0.0001	3.01 (2.34–3.87)	<0.0001	4.48 (3.22–6.22)	<0.0001
Pathologic nodal stage	pN+ vs. pN0–PNX	2.94 (1.72–5.01)	<0.0001	2.51 (1.75–3.60)	<0.0001	3.19 (2.01–5.04)	<0.0001
MULTIVARIATE ANALYSES
Invasiveness	Invasive vs. in situ	2.93 (1.53–5.63)	0.0013	1.80 (1.28–2.51)	0.0006	3.53 (1.86–6.71)	0.0001
Pathologic tumor size	>20 vs. ≤ 20 mm	1.22 (0.88–1.69)	0.2281	1.59 (1.28–1.97)	<0.0001	1.45 (1.09–1.94)	0.0102
Lymphovascular invasion	LVI+ vs. LVI–	2.67 (1.85–3.85)	<0.0001	2.25 (1.76–2.87)	<0.0001	2.95 (2.14–4.07)	<0.0001
Pathologic nodal stage	pN+ vs. pN0–PNX	1.58 (1.05–2.36)	0.0260	1.56 (1.17–2.08)	0.0020	1.66 (1.18–2.34)	0.0034